Thu, Aug 21, 2014, 12:39 AM EDT - U.S. Markets open in 8 hrs 51 mins


% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

grindle00 285 posts  |  Last Activity: 11 hours ago Member since: Feb 17, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • grindle00 grindle00 11 hours ago Flag

    It takes time to build up a following. The process is well underway. I don't think too many investors would confuse AMPE with a WS favored darling right now

  • grindle00 grindle00 12 hours ago Flag

    Here are some numbers that list total diabetic market sizes.

    About DME | Market Opportunity

    Diabetes mellitus is a chronic, multisystem disease that requires careful lifelong management and presently remains incurable.

    In 2010 it is estimated that 285 million people worldwide have diabetes mellitus and this figure is predicted to rise to over 438 million in the next 20 years. Improvements in the management of diabetes mellitus have significantly decreased the number of deaths as a direct result of the disease, so much so that vascular complications have now become the leading cause of morbidity and mortality among diabetics.

    Diabetic retinopathy is the most frequent vascular complication of diabetes and DME is the sight-threatening manifestation of diabetic retinopathy. DME is the leading cause of adult blindness in developed countries.

    This epidemic of diabetes with vascular complications coupled with an aging population and worldwide urbanisation is creating a huge medical burden on individuals and society.

    Approximately 20-25% of patients with diabetes will have DME threatening their vision, with an additional 2 million new cases diagnosed annually. Given the market size and substantial unmet clinical need, it is thought that a safe and effective treatment for DME could have multi-billion dollar annual sales revenue potential.

    Market Drivers

    In the absence of safe, effective treatments for DME, pharmaceutical sales for its management are relatively low, comprising predominantly off-label VEGF inhibitor use. However, in the next few years the pharmaceutical sales for the treatment of retinal disorders are projected to expand rapidly driven by the formal launch of VEGF inhibitors for DME as well as other new treatments.

  • grindle00 grindle00 13 hours ago Flag

    Refractory DME means the disease that doesn't respond to anti-VEGF drugs???

  • 55% of the patients in the Optina trial had no success with those blockbuster drugs. We apparently take the sickest of all patients in our trials (Ampion K3-K4 patients and now Optina). That's pretty kewl if you think about it

  • Reply to

    so, what if.......

    by hubby_14508 14 hours ago
    grindle00 grindle00 14 hours ago Flag

    Regeneration data is not part of STEP. That will be proved/dis-proved in the current 52 week trial

  • Wonder if we receive any updates from Citi or Jeffries or are they simply waiting for STEP results like everyone else

  • Reply to

    The people who are whining about

    by ja8713 Aug 19, 2014 2:08 PM
    grindle00 grindle00 15 hours ago Flag

    A patient long-term investor in a company. I thought all of those folks were dead. Nice post

  • grindle00 grindle00 15 hours ago Flag

    I vote for #1

  • Reply to

    The people who are whining about

    by ja8713 Aug 19, 2014 2:08 PM
    grindle00 grindle00 Aug 19, 2014 2:33 PM Flag

    Very common sense thoughts and proper logic when investing in small cap companies. Well said!! Don't see how you can get down-voted though (like we don't know who did that)

  • Reply to

    Well they did it

    by wc1200 Aug 19, 2014 10:02 AM
    grindle00 grindle00 Aug 19, 2014 11:51 AM Flag

    If I were a betting man I would probably bet against SVV making those timelines too. It's obviously turned out to be more difficult to migrate Iusacell's database than originally planned. I'm just trying to understand why I need to sell my stock because of this delay. People seem to already forget the "elephant" in the room.... Global Sales Collaboration with HP!! Here's an exchange I found interesting in the CC Q&A referencing how long this relationship has been in existence (translation kind of #$%$):

    Stan Berenshteyn - Sidoti & Company
    Okay, and can you maybe I guess maybe this is more subjective but can you give us an idea of the level of commitment HP has and providing the sales back into – pushing this product?
    Steven van der Velden
    Well, that’s quite difficult to quantify, I think they are very seriously working results, I think together with HP we have been visiting somewhere between 50 and 20 operators over the last 12 months around the world during in depth presentation supported by HP’s local presence in over 200 geographical markets and I believe all together it just open quite a few new doors and we feel confident that this is a very good stepping stone for Elephant Talk to upgrade this act and to be more proper supplier to many large companies that may not necessarily want to work with a small company like Elephant Talk but in combination with HP would definitely like to consider us. And I think from that perspective and what I’ve seen so far HP is very much positive and committed about his co-operation.

    Seems to me they may be further along in the sales process than most people think

  • Reply to

    Trend is looking good here.

    by golferstock1980 Aug 18, 2014 12:44 PM
    grindle00 grindle00 Aug 19, 2014 9:07 AM Flag

    The only trend I see is one of a flat-lining stock over the last 2 1/2-3 months. Anywhere between $.80-$.98 which isn't a huge range for a thinly traded micro-cap. I also like to see those type of charts because they tell me the stock is soon going one way or the other (of course I'm betting on the upside)

  • grindle00 grindle00 Aug 15, 2014 9:14 AM Flag

    Does a fully loaded Iusacell at $.25 per SIMM take the company to profitability?? What happens after that with any additional wins?? I think your calculation of $.25 per SIMM is low and I also believe it was prudent for the company to give a discount to Iusacell to show proof of concept

  • grindle00 grindle00 Aug 15, 2014 9:08 AM Flag

    The same CEO he constantly bashes executed the only 2 contracts I care about. The past is the past and the last time I looked stocks are valued on their future potential. The company is remaking itself and I don't care about the past. I also believe I have presented the negative side acknowledging past failures with VS, numerous failed ventures and inability to timely execute. Phoenix is nothing but a paid basher and anyone that believes he owned stock previously is very naïve. No one on the planet is so generous with their time and so-called knowledge to post non-stop on a message board where they own no stock

  • grindle00 grindle00 Aug 15, 2014 7:50 AM Flag

    While I can't argue with you about the committed short interest in the stock, the language present in the secondary prospectus is boilerplate and I have 1st hand knowledge of exactly where it came from because I sent it to the company. It came from VHC's 10-k

  • grindle00 grindle00 Aug 15, 2014 7:36 AM Flag

    Here are some FACTS:

    1) 12 consecutive quarters of growth with gross margins increasing from 15%-89%
    2) replaced incumbent IBM in the core of Iusacell' 8MM+ network
    3) signed a GLOBAL sales collaboration with top 4 Telco equipment provider that seems to have a nice seat at the table with Telcos that service over 200MM subscribers
    4) keeps expanding their business with Vodaphone, 1 of the top 3 Telcos in the world
    5) migration of Iusacell customer base makes the company profitable (my FACT, not proven yet)

    Here are some other #$%$ facts
    6) signed numerous deals over the past 3 years that have gone absolutely nowhere
    7) Validsoft is an anchor around their neck until proven otherwise (my opinion)
    8) Company doesn't have a track record of timely execution

    The negatives, other than timely execution, appear to be in the past. You make the decision to invest based on these FACTS, I know I have. Phoenix appears to be here to educate unsuspecting stupid retail investors. Others appear to be here to spread FUD (like you with your screen name). TGIF and Go Buckeyes!!!

  • Reply to

    What Price Will the Shorts Pay To Cover?

    by racavalli Aug 14, 2014 11:21 AM
    grindle00 grindle00 Aug 14, 2014 1:25 PM Flag

    Boy, did you get my reply wrong. The increase in short interest would be very recent if shorts new of bad test results ahead of time. Short interest hasn't gone up that much in the last 1-2 months. I was replying to Arnold and his contention that because of the high short interest the shorts know that results won't be good. I'm very long the stock and you'll never hear me whine about #$%$!!

  • Reply to

    What Price Will the Shorts Pay To Cover?

    by racavalli Aug 14, 2014 11:21 AM
    grindle00 grindle00 Aug 14, 2014 12:47 PM Flag

    If the "smartest guys in the room" weren't so prevalent in this stock over the last 3 years you're contention may hold water. Show me the dramatic increase in short interest that would obviously preclude the release of these "mediocre" results and I'd be forced to agree with you. These short market stats are not prevalent currently so I must disagree

  • grindle00 grindle00 Aug 14, 2014 10:58 AM Flag

    "next few days" does not explicitly mean 8/15/14. Please also don't confuse Validsoft and their past failures with ETAK's core mobile software division and their future potential. Night and day comparison. Nice try though

  • grindle00 grindle00 Aug 14, 2014 10:16 AM Flag

    One good thing about the HP sales collaboration should be HP's role in the migration process for any successful deals. We won't have to rely on SVV to miss any timelines. I would guess HP would be rather efficient

  • Reply to

    Why is there such a vengeful dislike for AMPE?

    by wiser_2000 Aug 13, 2014 3:40 PM
    grindle00 grindle00 Aug 14, 2014 7:32 AM Flag

    Here's the problem for the shorts. The science is real and the small company with no employees, CEO that's un-fit to lead, re-purposed drugs that are typically #$%$, and only 1 medical expert that knows what he's doing may have just hit on a rather lucrative drug. The cesspool that is the stock market of 2014 has all kinds of mechanisms to steal money from un-suspecting retail investors. These message boards being exhibit #1. Hard-bashers, Soft-bashers, Technical traders trying to convince LONG TERM INVESTORS how stupid they are for not trading. You know who makes $$ eventually in AMPE...... The stupidest investors out there who don't bother reading all of this #$%$!!!

7.46-0.08(-1.06%)Aug 20 4:01 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.